§ 15-859. Biomarker testing
West's Annotated Code of MarylandInsuranceEffective: January 1, 2024
Effective: January 1, 2024
MD Code, Insurance, § 15-859
§ 15-859. Biomarker testing
(2)(i) “Biomarker” means a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a specific therapeutic intervention, including known gene-drug interactions for medications being considered for use or already being administered.
(b) This section applies to:
(c) An entity subject to this section shall provide coverage for biomarker testing for the purpose of diagnosis, treatment, appropriate management, or ongoing monitoring of a disease or condition that is supported by medical and scientific evidence, including testing:
(d) An entity subject to this section shall ensure that the coverage required under subsection (c) of this section is provided in a manner that limits disruptions in care including the need for multiple biopsies or biospecimen samples.
(e)(1) Subject to paragraph (2) of this subsection, the coverage required under this section may be subject to the annual deductibles, copayments, or coinsurance requirements imposed by an entity subject to this section for similar coverages under the same health insurance policy or contract.
Credits
Added by Acts 2023, c. 322, § 1, eff. Jan. 1, 2024; Acts 2023, c. 323, § 1, eff. Jan. 1, 2024.
MD Code, Insurance, § 15-859, MD INSURANCE § 15-859
Current through legislation effective through June 1, 2024, from the 2024 Regular Session of the General Assembly. Some statute sections may be more current, see credits for details.
End of Document |